NCT00917826View on ClinicalTrials.gov

Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

September 30, 2009

Conditions
EBV LymphomasLympho-proliferative Diseases
Interventions
DRUG

Arginine Butyrate

1,000 mg/kg/day administered IV over 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)

DRUG

Ganciclovir

5 mg/kg administered IV over 1 hour (Days 1-5 of each 21 day cycle)

DRUG

Valganciclovir

900 mg BID for 16 days (Days 6-21 of each 21 day cycle)

Trial Locations (1)

07601

Hackensack University Medical Center, Hackensack

Sponsors
All Listed Sponsors
collaborator

Boston University

OTHER

lead

HemaQuest Pharmaceuticals Inc.

INDUSTRY